explore -WSS

explore

author：focus 2025-08-26 07:45:18 - browse：194

A photo of Robert Blum speaking at the STAT Summit West on May 16, 2024 — Cytokinetics CEO Robert Blum spoke Thursday at a talk during STAT’s Breakthrough Summit West in San Francisco. Sarah Gonzalez for STAT

As Cytokinetics faces pressure to sell itself to a large pharma company following positive late-stage results of its heart drug, CEO Robert Blum maintains that the biotech can launch the treatment — what would be its first approved medication — on its own.

Cytokinetics reported top-line results of its drug, aficamten, in obstructive hypertrophic cardiomyopathy, or oHCM, last December, sending its shares up on speculation the company would get acquired. Full Phase 3 results released this week further suggest the drug could be used more flexibly than a similar treatment sold by Bristol Myers Squibb, but investors have questioned whether the biotech has the resources and salesforce to compete with a large pharma company.

Blum, speaking Thursday at a talk during STAT’s Breakthrough Summit West, said that if prospective buyers approach the company, he will talk to them, but “at the same time, we’re pushing forward, as we always have, with the original intention to build a commercial business. And that’s not something new. That’s not something that’s a result of a failed M&A dialogue.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Multiple sclerosis has subtypes with different best treatments: study

WSS

Ionis drug prevents swelling attacks due to hereditary angioedema

How to increase colonoscopy rates? Looks like an AI can help

BMI, flaws aside, is found to be useful estimate of body fat in youth

U.K. decision on ALS drug has neurologists, advocates up in arms

Woman returns to dialysis after doctors remove transplanted pig kidney

Let's speed up science by embracing open access publishing

entertainment

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

In age of alternative facts, a scholarly course on calling out crap

Multiple sclerosis has subtypes with different best treatments: study

Supreme Court strikes down use of affirmative action

Multiple sclerosis has subtypes with different best treatments: study

Psychedelics group wrestles with new pharma identity

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Jerome Adams on the need for new antivirals for Covid

Scientific mystery highlights the blind spots in genomics databases

Hepatitis C has a cure — but many Americans still lack access to it

Mass General Brigham physicians react to latest merger step

focus

Let's speed up science by embracing open access publishing

First Opinion on colorectal cancer screening: letter and response

Scientific mystery highlights the blind spots in genomics databases

Kaiser's Risant Health gobbled up Geisinger. Who is next?

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

focus

focus

focus

entertainment